Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

A report/protocol for the optimisation of delivery of ribonucleoprotein (RNP) complexes into the patient derived DIPG cell line (SU-DIPG-IV) using electroporation. Electroporation was performed with the Neon electroporation system. RNPs consisting of sgRNA and AlexaFluor488 anti-mouse antibodies were used as a proxy for the Cas9/sgRNA RNPs to be delivered for CRISPR/Cas9 mediated genome editing.